Avalo (AVTX) CMO Doyle Mittie Exercises Options, Sells Shares

What Happened

• Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), exercised 679 stock options on August 28, 2026 at an exercise price of $8.04 per share (total cost $5,459) and sold the 679 shares the same day in an open-market transaction at $20.00 per share (total proceeds $13,580). The Form 4 also includes a derivative conversion entry reflecting the options being converted into common shares on exercise.

Key Details

• Transaction date: 2026-08-28
  • Exercise (M): 679 shares @ $8.04 — Acquired, $5,459 total
  • Sale (S): 679 shares @ $20.00 — Disposed, $13,580 total
  • Derivative conversion: 679 shares @ $0.00 — reflects option-to-stock conversion
• Shares owned after transaction: Not specified in the filing
• Footnotes:
  • The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Mittie on November 13, 2025 (F1).
  • The underlying option vests 25% on Jan 28, 2026, then monthly over the following three years (F2).
• Filing timeliness: Form 4 filed on 2026-09-01, which is within the two-business-day window following the Aug 28 transaction — appears timely.

Context

• This was an exercise followed by an immediate open-market sale of the resulting shares (exercise + same-day sale). Such transactions convert vested options into stock and then realize cash proceeds; they are common for executives monetizing vested equity. The presence of a pre-established Rule 10b5-1 plan indicates the sale was executed under a pre-set trading arrangement rather than an ad-hoc decision.